Cover Image
市場調查報告書

全球液態切片 (液態生物檢體) 市場機會 & 技術展望 2020年

Global Liquid Biopsy Market Opportunity & Technology Outlook 2020

出版商 KuicK Research 商品編碼 353999
出版日期 內容資訊 英文 105 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球液態切片 (液態生物檢體) 市場機會 & 技術展望 2020年 Global Liquid Biopsy Market Opportunity & Technology Outlook 2020
出版日期: 2016年03月09日 內容資訊: 英文 105 Pages
簡介

本報告以全球液態切片 (液態生物檢體) 市場為主題,提供液態切片概要與機制,補充液態切片市場的診斷技術的進步,使用無細胞循環腫瘤DNA的各適應症用臨床試驗,循環腫瘤細胞 & 無細胞腫瘤DNA的作用相關組合分析,各種液態切片技術的市場佔有率,及液態切片市場經營模式等相關資料,調查分析。

第1章 液態切片的簡介:非侵襲,診斷工具的改變遊戲規則者

第2章 作用機制:液態切片的主要零組件

  • 循環腫瘤細胞 (CTC)
  • 循環腫瘤核酸 (ctNA)
    • 無細胞DNA (ctDNA)
    • 其他循環腫瘤核酸:微型核糖核酸,mRNA及長鏈非編碼RNA
  • 外吐小體

第3章 循環腫瘤細胞:概要;歷史、生技藥品、選擇方法、檢測方法、增生方法、分析及疾病監測

  • 歷史、簡介
  • 選擇方法
  • 分析方法
  • 疾病監測範圍
  • 循環腫瘤細胞的生技藥品

第4章 補充診斷技術的進步的液態切片市場

  • 次世代定序技術概要
  • 包含在次世代定序的手法
    • 基因學
    • 轉錄體學
    • 外延基因組學
  • 使用次世代定序描寫基因分析的流程圖
    • 新一代定序的基本流程圖
    • 整合資料分析
  • 液態切片市場上次世代定序的價格推測

第5章 使用無細胞循環腫瘤DNA的各適應症的臨床試驗

  • 肺癌
  • 乳癌
  • 大腸癌
  • 黑色素瘤
  • 胃癌
  • 前列腺癌
  • 腦瘤
  • 第一型糖尿病的檢測 & 監測
  • 胰臟癌
  • 腎臟癌
  • 視網膜母細胞瘤

第6章 循環腫瘤細胞 & 無細胞腫瘤DNA的作用相關組合分析

第7章 液態切片的經營模式:新興企業、風險企業投資資金的溫床

第8章 液態切片相關的其他市場模式

  • CLIA (臨床檢驗改善修正法) 檢驗的認證評估:對液態切片來說的綠燈
  • 液態切片市場上服務供應商的影響
  • 保險相關問題觀點上液態切片所扮演的角色

第9章 北美、歐洲、亞太地區以及其他 (RoW) 的液態切片市場佔有率

  • 北美
  • 歐洲
  • 亞太地區
  • 其他 (RoW)
    • 非洲
    • 南美
    • 中東

第10章 推動市場的要素:液態切片臨床利用,為何那些是必須的?

  • 有助於(腫瘤的) 微小殘餘病變監測
  • 有助於追蹤藥物抗性的登場
  • 作為預測 & 藥效學生物標記所採用的液態切片

第11章 液態切片的市場趨勢:細胞活體組織切片的時代結束嗎?

第12章 各種液態切片技術的市場佔有率

第13章 市場課題:液態切片,是癌症診斷的革命;是神話還是現實?

  • 癌症細胞複雜的免疫-生物學機制
  • 假陽性液態切片檢驗的風險
  • 假陰性液態切片檢驗的風險
  • 癌症生物標記的未確定特性
  • 標準化通訊協定的缺乏
  • 經營模式為基礎的課題
  • 法律規範相關課題

第14章 結論:液態切片;即時 & 創新的新診斷工具

第15章 競爭情形

  • AdnaGen (QIAGEN)
  • Agena Bioscience
  • Angle
  • ApoCell
  • Biocept
  • BioFluidica
  • Bio-Rad Laboratories
  • Boreal Genomics
  • Chronix Biomedical
  • Clearbridge BioMedics
  • Cynvenio
  • Cytotrack
  • Epic Sciences
  • Exosome Diagnostics
  • Fluidigm
  • Fluxion Biosciences
  • Genomic Health
  • Guardant Health
  • HansaBiomed
  • Horizon Discovery
  • iCellate
  • Illumina
  • Inivata
  • Janssen Diagnostics
  • Molecular MD
  • Myriad Genetics
  • Natera

圖表清單

目錄

Biopsy is conducted to diagnose a disease, or to assess its progression so as to take an effective clinical action either by removing the affected site surgically or by drawing samples from the target tissue to conduct investigative studies about the disease. This technique is widespread and has been used since 12th century. The techniques involving solid biopsy have without any doubt, improved with advancement in scanning processes and surgical advancement. However, the traditional biopsy methods are of no match when it comes to the effective diagnosis and prognosis of cancer, besides ailments like renal failure, infections, fertility and transplantation related issues.

Liquid biopsy, on the other hand has offered us new insights in the diagnosis of diseases. It is the blood sample tests in which biomarkers associated with different disease are evaluated to determine the progression of a disease. This has allowed the emergence of targeted personalized diagnosis with increased efficiency outcomes and decreased diagnostic errors.

The emergence of liquid biopsy plays a vital role in prognosis as well as diagnostic studies for cancer treatment. Cancer has been one of the most difficult to be diagnosed at an early stage due to its fast mutation capabilities, immunosurveillance evading properties, circumventing growth suppressors among others. Besides, the genomic structure of cancer is highly unstable and in response to the therapy administered, cancer undergoes changes in their antigenic properties induced by mutations to escape immune action. Repeated tissue biopsy to assess the regression of the disease becomes cumbersome and dangerous for the patient. Therefore, the need arises for targeted therapy emerges, allowing real time monitoring to ensure that the targeted therapy is received by the cancer cells or to adopt a different biomarker in case the cancer cells mutate.

Liquid biopsy unlike normal biopsy is a non-invasive process in which samples can be drawn from blood, serum, saliva, urine or cerebral spinal fluid. Tissue biopsy on the other hand is invasive, costly, and painful and could be even risky in number of cases. Therefore, it becomes quite exciting to investigate the opportunities presented by liquid biopsies. For cancer diagnostic studies under liquid biopsy three techniques are normally used namely circulating tumor cells (CTCs), cell-free tumor nucleic acids (ctNA) and exosomes which includes small molecules like signal proteins, microRNAs, mRNAs, lipids, and exoDNA. Diagnosis of liquid biopsy is supplemented by the advancement in next generation sequencing techniques in which tumor cells, after they are captured, have their genomic and proteomic sequences run and analyzed using computational technologies to offer insight into the biomarkers associated with the respective tumor cells, which could then be in turn used for personalized diagnostic care.

“Global Liquid Biopsy Market Opportunity & Technology Outlook 2020” Report Highlights:

  • Introduction & Mechanism of Action of Liquid Biopsy
  • Diagnostic Technological Advancement Supplementing Liquid Biopsy Market
  • Clinical Investigation Using Cell-Free Circulating Tumor DNA for Different Indications
  • Combinational Analysis on the Working of Circulating Tumor Cells & Cell-Free Tumor DNA
  • Market Share of Different Liquid Biopsy Techniques
  • Business Model of Liquid Biopsy Market

Table of Contents

1. Introduction to Liquid Biopsy: A Non-Invasive, Game-Changer Diagnostic Tool

2. Mechanism of Action: Major Components of Liquid Biopsy

  • 2.1. Circulating Tumor Cells
    • 2.1.1. Parameters Guiding Circulating Cell Tumors
  • 2.2. Circulating Tumor Nucleic Acids (ctNA)
    • 2.2.1. Cell-Free Tumor DNA
    • 2.2.2. Other Circulatory Tumor Nucleic Acid: microRNA, mRNA & Long Non-Coding RNAs
  • 2.3. Exosomes

3. Circulatory Tumor Cells: A Snapshot; Its History, Biologics, Selection Method, Detection Procedures, Enrichment Procedures, Analysis & Disease Monitoring

  • 3.1. The History & Introduction
  • 3.2. The Selection Methods
  • 3.3. The Analysis Methodologies
  • 3.4. The Scope of Disease Monitoring
  • 3.5. The Biologics of Circulatory Tumor Cells

4. Diagnostic Technological Advancement Supplementing Liquid Biopsy Market

  • 4.1. Glimpses to the Next Generation Sequencing Techniques
  • 4.2. Methodologies Involved in the Next Generation Sequencing
    • 4.2.1. Genomics
    • 4.2.2. Transcriptomics
    • 4.2.3. Epigenomics
  • 4.3. Flowchart Depicting Genomic Analysis Using Next Generation Sequencing
    • 4.3.1. A Basic Workflow of Next Generation Sequencers
    • 4.3.2. Integrated Data Analysis
  • 4.4. Pricing Implications of Next Generation Sequencing On the Liquid Biopsy Market

5. Clinical Investigation Using Cell-Free Circulating Tumor DNA for Different Indications

  • 5.1. Lung Cancer
  • 5.2. Breast Cancer
  • 5.3. Colorectal Cancer
  • 5.4. Melanoma
  • 5.5. Gastric Cancer
  • 5.6. Prostate Cancer
  • 5.7. Brain Cancer
  • 5.8. Detection & Monitoring of Type 1KKKKK Diabetes
  • 5.9. Pancreatic Cancer
  • 5.10. Renal Cancer
  • 5.11. Retinoblastoma

6. Combinational Analysis on the Working of Circulating Tumor Cells & Cell-Free Tumor DNA

7. Business Model of Liquid Biopsy Market: A Hotbed for Start-Ups and Venture Capital Funding

8. Other Market Modalities Associated With Liquid Biopsy

  • 8.1. Accreditation through Clinical Laboratory Improvement Amendments (CLIA) Testing: Green Signal for Liquid Biopsy
  • 8.2. The Impact of Service Providers in Liquid Biopsy Market
  • 8.3. The Role of Liquid Biopsy In The Light Of Insurance Associated Issues

9. Liquid Biopsy Market Share in North America, Europe, Asia- Pacific & Rest of the World

  • 9.1. North America
  • 9.2. Europe
  • 9.3. Asia-Pacific
  • 9.4. Rest of the World
    • 9.4.1. Africa
    • 9.4.2. South America
    • 9.4.3. Middle East

10. Market Drivers: Clinical Utilities of Liquid Biopsy. Why Do We Need Them?

  • 10.1. Help Monitor Minimal Residue Disease
  • 10.2. Help Track Emergence of Drug Resistance
  • 10.3. Liquid Biopsy Used As a Predictive & Pharmacodynamic Biomarker
    • 10.3.1. Cell-Free Tumor DNA as Predictive Biomarker
    • 10.3.2. Cell-Free Tumor DNA as Pharmacodynamic Biomarker

11. Market Trends in Liquid Biopsy. Is The Era Of Tissue Biopsy Coming To An End?

12. Market Share of Different Liquid Biopsy Techniques

13. Market Challenges: Liquid biopsy, A Revolution in Cancer Diagnosis; a Myth or a Reality?

  • 13.1. Complex Immuno-Biochemical Mechanism of Cancer Cells
  • 13.2. The Risk of False Positive Liquid Biopsy Test
  • 13.3. The Risk of False Negative Liquid Biopsy Test
  • 13.4. Inconclusive Nature of Cancer Biomarkers
  • 13.5. Lack of Standardized Protocols
  • 13.6. Business Model Based Challenges
  • 13.7. Issues Related To Regulatory Framework

14. Conclusion: Liquid Biopsy; Real-Time & Revolutionary Novel Diagnostic Tool

15. Competitive Landscape

  • 15.1. AdnaGen (QIAGEN)
  • 15.2. Agena Bioscience
  • 15.3. Angle
  • 15.4. ApoCell
  • 15.5. Biocept
  • 15.6. BioFluidica
  • 15.7. Bio-Rad Laboratories
  • 15.8. Boreal Genomics
  • 15.9. Chronix Biomedical
  • 15.10. Clearbridge BioMedics
  • 15.11. Cynvenio
  • 15.12. Cytotrack
  • 15.13. Epic Sciences
  • 15.14. Exosome Diagnostics
  • 15.15. Fluidigm
  • 15.16. Fluxion Biosciences
  • 15.17. Genomic Health
  • 15.18. Guardant Health
  • 15.19. HansaBiomed
  • 15.20. Horizon Discovery
  • 15.21. iCellate
  • 15.22. Illumina
  • 15.23. Inivata
  • 15.24. Janssen Diagnostics
  • 15.25. Molecular MD
  • 15.26. Myriad Genetics
  • 15.27. Natera

List of Figures

  • Figure 1-1: Limitations of Tissue Biopsy
  • Figure 1-2: Hallmarks of Cancer Cells
  • Figure 1-3: Advantages of Liquid Biopsy
  • Figure 2-1: Major Components of Liquid Biopsy
  • Figure 2-2: Properties of Circulatory Tumor Cells
  • Figure 2-3: Techniques Guiding Circulating Cell Tumors Separation
  • Figure 2-4: Cell-Free Tumor DNA
  • Figure 2-5: Other Circulatory Tumor Nucleic Acid
  • Figure 2-6: Exosomes Based Liquid Biopsy
  • Figure 3-1: Introduction to Circulatory Tumor Cells
  • Figure 3-2: Selection Methods of Circulating Tumor Cells
  • Figure 3-3: The Analysis Methodologies for Circulatory Tumor Cells
  • Figure 3-4: The Scope of Disease Monitoring With Circulatory Tumor Cell
  • Figure 3-5: The Biologics of Circulatory Tumor Cells
  • Figure 4-1: Methodologies Involved In the Next Generation Sequencing
  • Figure 4-2: Genomics Attributes of Next Generation Sequencing
  • Figure 4-3: Proteomic Attributes of Next Generation Sequencing
  • Figure 4-4: Epigenomic Attributes of Next Generation Sequencing
  • Figure 4-5: Flowchart Depicting Genomic Analysis Using Next Generation Sequencing
  • Figure 4-6: Pricing Implications of Next Generation Sequencing On the Liquid Biopsy Market
  • Figure 5-1: Liquid Biopsy for Detection of Lung Cancer
  • Figure 5-2: Liquid Biopsy for Detection of Breast Cancer
  • Figure 5-3: Liquid Biopsy for Detection of Colorectal Cancer
  • Figure 5-4: Liquid Biopsy for Detection of Melanoma
  • Figure 5-5: Liquid Biopsy for Detection of Gastric Cancer
  • Figure 5-6: Liquid Biopsy for Detection of Prostate Cancer
  • Figure 5-7: Liquid Biopsy for Detection of Brain Cancer
  • Figure 5-8: Detection & Monitoring of Type 1 Diabetes
  • Figure 5-9: Liquid Biopsy for Detection of Pancreatic Cancer
  • Figure 5-10: Liquid Biopsy for Detection of Renal Cancer
  • Figure 5-11: Liquid Biopsy for Detection of Retinoblastoma
  • Figure 6-1: Circulating Tumor Cells & Cell-free Tumor DNA
  • Figure 6-2: Differential Study of Circulating Tumor Cells & Cell-free Tumor DNA
  • Figure 7-1: Liquid Biopsy for Start-Ups & Venture Capitalists; Favorable Factors
  • Figure 8-1: Accreditation Program for Liquid Biopsy
  • Figure 8-2: Service Providers in Liquid Biopsy Market
  • Figure 8-3: Liquid Biopsy & Insurance Coverage Plans
  • Figure 9-1: Liquid Biopsy Market in North America
  • Figure 9-2: Liquid Biopsy Market in Europe
  • Figure 9-3: Liquid Biopsy Market in Asia-Pacific Region
  • Figure 9-4: Liquid Biopsy Market in Rest of the World
  • Figure 10-1: Liquid Biopsy in Monitoring Minimal Residual Disease
  • Figure 10-2: Liquid Biopsy in Tracking Emergence of Drug Resistance
  • Figure 10-3: Liquid Biopsy as a Predictive & Pharmacodynamic Biomarker
  • Figure 11-1: Market Trends in Liquid Biopsy
  • Figure 12-1: Liquid Biopsy Market by Technique
  • Figure 13-1: Market Challenges Associated With Liquid Biopsy
Back to Top